Expert consensus on the diagnosis and treatment in advanced non-small cell lung cancer with BRAF mutation in China / 中华肿瘤杂志
Chinese Journal of Oncology
;
(12): 279-290, 2023.
Artigo
em Chinês
| WPRIM
| ID: wpr-980722
ABSTRACT
Lung cancer is the malignant tumor with the highest incidence and mortality rate in China, among which non-small cell lung cancer (NSCLC) accounts for about 85%. BRAF mutation occurs about 1.5% to 5.5% in NSCLC patients, while BRAF V600 accounts for about 30% to 50% of all BRAF mutations. The overall prognosis of patients with BRAF-mutation is poor. At present, there are many clinical trials on BRAF-mutation NSCLC and new drugs constantly emerging. However, there is no standardized consensus on the diagnosis and treatment of BRAF-mutation NSCLC in China. The expert group of the Lung Cancer Professional Committee of the Chinese Anti-Cancer Association formulated this consensus by integrating foreign and domestic BRAF-mutation-related guidelines, consensus, and existing clinical trials, and combining with Chinese experts' clinical experience in the diagnosis and treatment of BRAF-mutation NSCLC. This consensus provides systematic recommendations for the clinical diagnosis and treatment process, rational drug choice, and adverse events management of BRAF-mutation NSCLC, aiming to provide reference for the standard of diagnosis and treatment of BRAF-mutation NSCLC.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Assunto principal:
Carcinoma Pulmonar de Células não Pequenas
/
Consenso
/
Proteínas Proto-Oncogênicas B-raf
/
Neoplasias Pulmonares
/
Mutação
Limite:
Humanos
Idioma:
Chinês
Revista:
Chinese Journal of Oncology
Ano de publicação:
2023
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS